Specimens. Sera obtained from adolescents and adults symptomatic for the mononucleosis syndrome were processed in our laboratory. These patients were seen at various clinics and physicians' offices in the local community. All specimens were tested within 3 days of receipt. Most of the specimens (214 [86%] of 247) were tested within 6 h after collection. Sera that could not be tested promptly were stored frozen at or below -20°C and subsequently tested within 3 days of receipt.
Infectious mononucleosis (IM) is an acute, self-limited, lymphoproliferative disease caused by the Epstein-Barr virus (EBV). Infection with EBV usually occurs early in life with no recognizable disease. When primary infection is delayed until young adulthood and adolescence, however, there is about a 50% chance that it will occur with the classic clinical manifestations associated with IM (2, 3) .
The diagnosis of IM is usually based on evaluation of characteristic clinical, hematologic, and serologic changes (2, 8, 9) . Because other diseases may mimic the clinical symptoms of IM, serologic testing is essential for the most accurate diagnosis. Serologic diagnosis of IM is demonstrated by the presence of heterophil and EBV antibodies in the sera of patients (2, (7) (8) (9) .
It has been well established that most individuals exposed to EBV develop a heterophil antibody response. Heterophil antibodies make up a broad class of antibodies which are characterized by the ability to react with surface antigens present on erythrocytes (RBCs) of different mammalian species. There are heterophil antibodies which appear in IM that are referred to as IM-specific or IM heterophil antibodies, and they are of the immunoglobulin M (IgM) class. These antibodies do not react with EBV antigens, and it is unknown which specific antigen stimulates their production. IM Overall, the two tests were in agreement. When they differed, EBV serology profiles were able to provide a basis for presumptive and not necessarily firm diagnosis. EBV antibody profiles can be helpful in determining the presence and stage of the disease. However, a definitive EBV diagnosis is not a simple matter and antibody titers may be interpreted differently in different laboratories (10) . The question of agreement of EBV profiles with heterophil screening tests when the tests agree (i.e., when both are positive or negative) was not pursued in this study but was addressed in an earlier study by Tilton et al. (13) . In that study, there was complete agreement between the screen results and EBV profiles when a random number of samples from patients were studied.
The 
